You are here

Article Text

Article menu
Download PDFPDF
Letter
Rituximab treatment for peripheral ulcerative keratitis associated with Wegener’s granulomatosis
  1. Julie Freidlin,
  2. Ira G Wong,
  3. Nisha Acharya
  1. F I Proctor Foundation, 95 Kirkham Street, University of California, San Francisco, CAlifornia, USA
  1. Nisha Achanrya, F I Proctor Foundation, 95 Kirkham Street, University of California, San Francisco, CA 94143, USA; Nisha.Acharya{at}yahoo.com

https://doi.org/10.1136/bjo.2006.113316

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rituximab is a chimeric antibody against CD20 aimed at depleting B cells. While originally developed as a treatment for B cell lymphomas, it was recently found to be useful in managing autoimmune diseases including refractory Wegener’s granulomatosis.1–3 We report a case of refractory peripheral ulcerative keratitis (PUK) associated with Wegener’s granulomatosis that was successfully treated with rituximab.

    Case report

    A 57 year old man with longstanding Wegener’s granulomatosis was admitted to the hospital with severe pain and blurred vision in the left eye as well as respiratory compromise because of tracheal …

    View Full Text

    Footnotes

    • Competing interests: None.

    • Informed consent was obtained for publication of figures 1 and 2.